BMS, Pfizer and Merck face steep patent cliffs but all have the financial flexibility for M&A: Moody's

Bristol Myers Squibb, Pfizer and Merck will face extreme patent cliff exposure later in this decade. But those companies also have the financial flexibility to perform mergers and acquisitions to overcome the anticipated losses.